Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Disposal of Investment

5 Jan 2005 07:00

BioProjects International PLC05 January 2005 BIOPROJECTS INTERNATIONAL PLC ("BIOPROJECTS") DISPOSAL OF STAKE IN ACOLYTE BIOMEDICA BioProjects announces that it has entered into a conditional agreement withPorton Capital Ltd for the sale of the whole of its shareholding in AcolyteBiomedica Ltd ("Acolyte"), the company that is developing a range of productsfor rapid detection of sepsis, blood infections and antibiotic resistance. "Porton Capital is already a substantial shareholder in Acolyte and the companyapproached us because it wanted to increase its stake," said chairman Mr. JimSlater. "BioProjects specialises in the financing of early-stage companies andwe consider it opportune now to take a reasonable profit and increase our cashresources." BioProjects will receive cash consideration of £2.5 million (net) forshareholding in Acolyte, which is a premium of approximately £500,000 over costand approximately £750,000 over book value. Further information from: Terry Bond, Managing Director, BioProjectsInternational. 01235 834734 or mobile 07860 842756. This information is provided by RNS The company news service from the London Stock Exchange

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.